Frost & Sullivan: Global Pharma Enters 'Decisive Reset' as AI, Biologics, and Supply Resilience Redefine Growth Through 2031
核心洞察
Frost & Sullivan (搜索)'s 2026 analysis identifies a profound industry transformation driven by affordability mandates, patent expiries, geopolitical fragmentation, and rapid technological advances.
Five defining themes include compressed value-capture windows, deliverability as competitive advantage, selective innovation models, supply resilience as strategic imperative, and AI moving into governed workflows.
Biologics and next-generation modalities such as GLP-1 therapies (搜索), ADCs, radioligand therapies (搜索), and cell and gene therapies (搜索) represent concentrated growth opportunities.
The global pharmaceutical industry is entering a period of profound transformation as affordability mandates, patent expiries, geopolitical fragmentation, and rapid technological advances reshape the foundations of value creation, according to Frost & Sullivan (搜索)'s latest analysis, Growth Opportunities in Global Pharmaceutical Industry, 2026.
"2026 marks a decisive reset for global biopharma," said Surbhi Gupta, Industry Principal at Frost & Sullivan (搜索). "Commercial success will depend less on historical peak-sales models and more on how quickly companies can generate evidence, secure market access, integrate innovation, and reliably deliver advanced therapies in increasingly complex operating environments."
The study finds that traditional drivers of success are being replaced by a new set of competitive imperatives centred on execution excellence, supply resilience, AI-enabled operations, and the ability to commercialise increasingly complex therapeutic modalities at scale.
Five Themes Defining the Next Phase of Growth
The analysis highlights five interconnected themes that will define industry growth through 2031. First, policy reforms, accelerating patent expiries, and intensifying pricing pressures are compressing traditional value-capture windows, forcing organisations to generate evidence earlier, strengthen lifecycle management strategies, and accelerate market access efforts.
Second, deliverability is emerging as a critical source of competitive advantage. Manufacturing readiness, cold-chain integrity, quality assurance, and site-of-care preparedness are becoming essential differentiators in an era of increasingly sophisticated therapies.
Third, innovation models are evolving as pharmaceutical companies become more selective in their investments, prioritising scalable assets, high-conviction opportunities, and their ability to rapidly integrate and operationalise external innovation.
Fourth, supply resilience has shifted from an operational concern to a strategic imperative, as governments and regulators place greater emphasis on localisation, continuity, and security of supply amid geopolitical uncertainty.
Finally, artificial intelligence is moving beyond experimentation into governed, audit-ready workflows embedded across discovery, clinical operations, quality, manufacturing, and commercial functions, creating the foundations for more efficient and data-driven operating models.
Biologics and Next-Generation Modalities Lead Growth
Frost & Sullivan (搜索) notes that growth opportunities are increasingly concentrated around biologics and next-generation modalities, including GLP-1 therapies (搜索), antibody-drug conjugates (搜索) (ADCs), radioligand therapies (搜索), and cell and gene therapies (搜索). Surrounding ecosystems such as obesity care operating systems, specialised manufacturing capabilities, and confirmatory-ready clinical trial models offer significant whitespace opportunities.
The study also forecasts a divergence in growth trajectories between traditional small molecules and large molecules. While small molecules will remain the industry's cash-flow backbone, biologics are expected to continue expanding their share of the market as companies invest in advanced therapeutic platforms and industrial-scale execution capabilities.
A Call for Operating Model Transformation
"Pharma companies can no longer treat these pressures as a series of incremental challenges," Gupta concluded. "The organisations that thrive will be those willing to rebuild their operating models around resilience, speed, disciplined innovation, and scalable execution."
The report underscores that future winners will be those that can execute faster, industrialise innovation, and navigate mounting pricing and geopolitical pressures in an increasingly complex global landscape.